Reviva Pharmaceuticals’ (RVPH) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $2.00 target price on the stock.

A number of other research analysts have also recently issued reports on the company. Benchmark cut their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $3.86.

Reviva Pharmaceuticals Trading Up 7.1%

NASDAQ RVPH opened at $0.35 on Monday. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.15. The company has a market capitalization of $39.83 million, a price-to-earnings ratio of -0.75 and a beta of 0.08. The stock’s 50 day moving average is $0.51 and its two-hundred day moving average is $0.49.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. On average, analysts predict that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of large investors have recently modified their holdings of RVPH. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the first quarter valued at approximately $58,000. XTX Topco Ltd bought a new position in Reviva Pharmaceuticals in the 2nd quarter valued at $31,000. Lido Advisors LLC bought a new position in Reviva Pharmaceuticals in the 3rd quarter valued at $37,000. Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares during the period. Finally, Persistent Asset Partners Ltd raised its position in shares of Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after acquiring an additional 480,864 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.